Matches in SemOpenAlex for { <https://semopenalex.org/work/W2584746054> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2584746054 abstract "Abstract Abstract 4877 Adult T-cell leukemia/lymphoma (ATLL) carries a dismal long-term prognosis and is generally chemotherapy resistant. We and other groups have demonstrated that the combination of AZT and interferon (IFN) alpha can effectively suppress ATLL long-term; however, these drugs fail to eradicate malignant ATLL clones as patients ultimately progress. We recently tested our hypothesis that histone deacelytase (HDAC) inhibitors would re-activate latent HTLV-I in ATLL cells harboring intact provirus thus helping to eliminate residual disease after cytoreductive treatment. Histone acetylation can result in HTLV-I promoter activation and viral transcription. We found that HDAC inhibitors, including the inexpensive drug valproic acid (VPA), reactivated HTLV-I expression in ATLL cells and caused apoptosis. Based on these concepts, we recently completed a pilot trial for ATLL using AZT/IFN and adding VPA during the maintenance treatment phase. Thirteen subjects with aggressive acute-type ATLL were enrolled in the study, including 11 treatment-naïve patients. The estimated 12-month overall survival rate was 46%. In 12 evaluable subjects (10 naïve) the complete response (CR) rate was 33% and overall response 42% (5 patients). A total of eight subjects (66%) had a hematologic response, including 5 complete hematologic responses (38%). VPA was added at the beginning of month 3 during AZT/IFN maintenance in 3 subjects. One subject achieved a molecular remission and clearance of ATLL after adding VPA as measured by serial multiplex PCR studies. This subject remains disease-free 2.5 years later. Our findings were surprising, as previous studies performed on long-term responders treated with AZT/IFN alone had not demonstrated any molecular remissions. Our data suggest that VPA could potentially eradicate ATLL clones in vivo. The dual anti-neoplastic and viral inducing roles of HDAC inhibitors can be exploited in the treatment of ATLL. This exciting approach may help advance the cure for this disease. We will present our updated interim clinical trial results at the conference. Disclosures: No relevant conflicts of interest to declare." @default.
- W2584746054 created "2017-02-10" @default.
- W2584746054 creator A5004461697 @default.
- W2584746054 creator A5034926432 @default.
- W2584746054 creator A5037735219 @default.
- W2584746054 creator A5069533756 @default.
- W2584746054 creator A5072469379 @default.
- W2584746054 creator A5074962892 @default.
- W2584746054 creator A5091650487 @default.
- W2584746054 date "2012-11-16" @default.
- W2584746054 modified "2023-09-28" @default.
- W2584746054 title "The Combination of AZT/Interferon-α Therapy with the HDAC Inhibitor Valproic Acid for the Treatment of Adult T-Cell Leukemia/Lymphoma" @default.
- W2584746054 doi "https://doi.org/10.1182/blood.v120.21.4877.4877" @default.
- W2584746054 hasPublicationYear "2012" @default.
- W2584746054 type Work @default.
- W2584746054 sameAs 2584746054 @default.
- W2584746054 citedByCount "0" @default.
- W2584746054 crossrefType "journal-article" @default.
- W2584746054 hasAuthorship W2584746054A5004461697 @default.
- W2584746054 hasAuthorship W2584746054A5034926432 @default.
- W2584746054 hasAuthorship W2584746054A5037735219 @default.
- W2584746054 hasAuthorship W2584746054A5069533756 @default.
- W2584746054 hasAuthorship W2584746054A5072469379 @default.
- W2584746054 hasAuthorship W2584746054A5074962892 @default.
- W2584746054 hasAuthorship W2584746054A5091650487 @default.
- W2584746054 hasConcept C118552586 @default.
- W2584746054 hasConcept C126322002 @default.
- W2584746054 hasConcept C143998085 @default.
- W2584746054 hasConcept C203014093 @default.
- W2584746054 hasConcept C2776238826 @default.
- W2584746054 hasConcept C2776694085 @default.
- W2584746054 hasConcept C2776913467 @default.
- W2584746054 hasConcept C2777172819 @default.
- W2584746054 hasConcept C2778041864 @default.
- W2584746054 hasConcept C2778186239 @default.
- W2584746054 hasConcept C2778461978 @default.
- W2584746054 hasConcept C2779338263 @default.
- W2584746054 hasConcept C2780815077 @default.
- W2584746054 hasConcept C502942594 @default.
- W2584746054 hasConcept C71924100 @default.
- W2584746054 hasConceptScore W2584746054C118552586 @default.
- W2584746054 hasConceptScore W2584746054C126322002 @default.
- W2584746054 hasConceptScore W2584746054C143998085 @default.
- W2584746054 hasConceptScore W2584746054C203014093 @default.
- W2584746054 hasConceptScore W2584746054C2776238826 @default.
- W2584746054 hasConceptScore W2584746054C2776694085 @default.
- W2584746054 hasConceptScore W2584746054C2776913467 @default.
- W2584746054 hasConceptScore W2584746054C2777172819 @default.
- W2584746054 hasConceptScore W2584746054C2778041864 @default.
- W2584746054 hasConceptScore W2584746054C2778186239 @default.
- W2584746054 hasConceptScore W2584746054C2778461978 @default.
- W2584746054 hasConceptScore W2584746054C2779338263 @default.
- W2584746054 hasConceptScore W2584746054C2780815077 @default.
- W2584746054 hasConceptScore W2584746054C502942594 @default.
- W2584746054 hasConceptScore W2584746054C71924100 @default.
- W2584746054 hasLocation W25847460541 @default.
- W2584746054 hasOpenAccess W2584746054 @default.
- W2584746054 hasPrimaryLocation W25847460541 @default.
- W2584746054 hasRelatedWork W169212195 @default.
- W2584746054 hasRelatedWork W1897827045 @default.
- W2584746054 hasRelatedWork W1928198940 @default.
- W2584746054 hasRelatedWork W1980348902 @default.
- W2584746054 hasRelatedWork W2017131345 @default.
- W2584746054 hasRelatedWork W2018378578 @default.
- W2584746054 hasRelatedWork W2028624655 @default.
- W2584746054 hasRelatedWork W2032605246 @default.
- W2584746054 hasRelatedWork W2081100261 @default.
- W2584746054 hasRelatedWork W2111510691 @default.
- W2584746054 hasRelatedWork W2124529004 @default.
- W2584746054 hasRelatedWork W2161289362 @default.
- W2584746054 hasRelatedWork W2425641831 @default.
- W2584746054 hasRelatedWork W2460539770 @default.
- W2584746054 hasRelatedWork W2557854027 @default.
- W2584746054 hasRelatedWork W2583965938 @default.
- W2584746054 hasRelatedWork W2599686852 @default.
- W2584746054 hasRelatedWork W2975436115 @default.
- W2584746054 hasRelatedWork W3016345828 @default.
- W2584746054 hasRelatedWork W3174213510 @default.
- W2584746054 isParatext "false" @default.
- W2584746054 isRetracted "false" @default.
- W2584746054 magId "2584746054" @default.
- W2584746054 workType "article" @default.